Overview:

The management of esophagogastric adenocarcinoma has evolved substantially with the introduction of effective targeted and immunologic therapies. However, these therapies are appropriate mainly for patients with specific biomarkers, necessitating careful coordination among the multidisciplinary team to ensure proper tissue stewardship and testing, which in turn allows for appropriate treatment selection and sequencing, as well as management and mitigation of adverse events.

In this series of live, virtual webcasts, experts in the management of esophagogastric adenocarcinoma discuss the evaluation and treatment of HER2-positive disease across the treatment continuum. Each program in the series addresses distinct clinical challenges, from first-line treatment selection through management of progression and adverse events associated with HER2-directed therapies. These points are discussed in the context of patient case scenarios that reflect the decisions clinicians encounter in practice.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Apply best practices for HER2 biomarker testing in patients with GEA to guide timely, individualized treatment decisions
• Evaluate emerging clinical trial data assessing novel HER2-targeted treatment strategies for GEA
• Incorporate the latest evidence on HER2-directed therapies into individualized treatment plans for patients with advanced GEA
• Implement strategies to mitigate and manage AEs associated with HER2-targeted therapy

Target Audience:

This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses who are involved in the management of patients with advanced or metastatic gastroesophageal cancers (GEAs).

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Acknowledgment of Educational Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Have a question for the PER® team?

Oncology Inquiries: onc-info@gotoper.com

Eye Care Inquiries: eye-info@gotoper.com

Multispecialty Inquiries: multi-info@gotoper.com